Picamilon – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Picamilon is a Russian-developed conjugate of niacin (vitamin B3) and GABA. The niacin portion carries GABA across the blood-brain barrier. Used in Russia for circulation and anxiety. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Soviet-era niacin-GABA prodrug with clever BBB concept but thin modern evidence and limited research utility

Look, the core idea behind picamilon was actually clever for 1975. GABA doesn’t cross the blood-brain barrier on its own, so Soviet pharmacologists conjugated it to niacin, which does. Central hydrolysis was supposed to release both components and produce a combined anxiolytic-plus-vasodilatory effect. As a prodrug strategy, its fine. The problem is that we’ve known exactly how this works for decades, the components are completely mundane, and the literature supporting it is almost entirely Soviet-era Russian research that isn’t held to the methodological standards we’d want to see today.

On novelty, there’s nothing to argue about. The compound is fifty years old, approved in Russia for cerebrovascular insufficiency and anxiety, and the mechanism has been understood since its original synthesis. The niacin vasodilation story is textbook pharmacology; the GABA-ergic anxiolysis is equally unremarkable. What the conjugation adds is BBB penetrance, which is a real pharmacological contribution, but that contribution was made a long time ago and doesn’t translate into research excitement now.

The evidence situation is genuinely problematic. The clinical literature lives almost exclusively in Soviet and Russian journals from the 1970s through 1990s, with the methodological limitations that implies. There’s no meaningful Western replication. Russia’s national approval reflects a different regulatory context and era. The FDA has explicitly issued warnings against picamilon’s sale as a dietary supplement in the United States, citing that it doesn’t meet the legal definition of a dietary ingredient. That’s not a disqualifier for a research-use compound, but it does signal how regulators are reading the evidence base.

From a bench utility perspective, we struggle to identify what question picamilon lets you answer that you couldn’t answer better with other tools. For central GABA biology, phenibut and the benzodiazepine pharmacology toolbox are more characterized. For cerebrovascular work, there are better vasodilatory probes. For anxiolysis research, the GABA-A positive allosteric modulator literature is far more sophisticated. Picamilon sits at the intersection of several areas without being the best tool in any of them.

Honestly, the compound’s most interesting research angle might be as a case study in Soviet psychopharmacology and the BBB-penetrant prodrug design philosophy. That’s historically interesting but it’s not going to move a modern research program. We think the compound is fine as a historical artifact and the original prodrug concept still has teaching value, but as an object of new bench-scale investigation, there are better places to put time and resources in 2025.

Novelty: 22
Mechanism promise: 32
In-category differentiation: 28
Evidence quality: 30
Translational signal: 33
Research bench value: 22

Rationale Picamilon scores low primarily because both the novelty and the bench utility are exhausted: the BBB-penetrant GABA prodrug concept was genuinely clever in the 1970s but the underlying biology is now utterly mundane, and the evidence base is almost entirely Soviet-era Russian literature that doesn’t meet modern methodological standards. The Russian national approval gives it minimal translational credit, but there’s essentially no Western replication and better probes exist for every niche this compound occupies.

Niacin-GABA conjugate

A Soviet-developed niacin-GABA conjugate (N-nicotinoyl-GABA) that crosses the blood-brain barrier and dissociates centrally to release both components.

Abstract

Picamilon (Pikamilon; N-nicotinoyl-GABA; CAS 34562-97-5; molecular formula C10H12N2O3; molecular weight 208.21) is a conjugate of niacin (nicotinic acid) and GABA developed in the Soviet Union in the 1970s. The niacin moiety provides blood-brain barrier permeability that GABA lacks; central hydrolysis releases both components. Niacin produces vasodilation and the GABA produces anxiolytic and mild sedative effects. The combination is approved in Russia for cerebrovascular insufficiency, anxiety, and migraine prophylaxis. Pharmacokinetics: rapid oral absorption; central hydrolysis to niacin and GABA; the niacin component is hepatically conjugated and excreted while GABA is metabolized through normal GABA pathways. Doses are 50 to 300 mg per day in divided administrations. The compound is sold as a research chemical/supplement in the United States though FDA has issued warnings against its sale as a dietary supplement.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-068Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.